| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Priority Reports |
Department of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands
Requests for reprints: Ivo P. Touw, Department of Hematology, Erasmus University Medical Center, Rotterdam, P.O. Box 1738, 3000 DR Rotterdam, the Netherlands. Phone: 31-10-408-7837; Fax: 31-10-408-9470; E-mail: i.touw{at}erasmusmc.nl.
Retroviral insertion mutagenesis is considered a powerful tool to identify cancer genes in mice, but its significance for human cancer has remained elusive. Moreover, it has recently been debated whether common virus integrations are always a hallmark of tumor cells and contribute to the oncogenic process. Acute myeloid leukemia (AML) is a heterogeneous disease with a variable response to treatment. Recurrent cytogenetic defects and acquired mutations in regulatory genes are associated with AML subtypes and prognosis. Recently, gene expression profiling (GEP) has been applied to further risk stratify AML. Here, we show that mouse leukemia genes identified by retroviral insertion mutagenesis are more frequently differentially expressed in distinct subclasses of adult and pediatric AML than randomly selected genes or genes located more distantly from a virus integration site. The candidate proto-oncogenes showing discriminative expression in primary AML could be placed in regulatory networks mainly involved in signal transduction and transcriptional control. Our data support the validity of retroviral insertion mutagenesis in mice for human disease and indicate that combining these murine screens for potential proto-oncogenes with GEP in human AML may help to identify critical disease genes and novel pathogenetic networks in leukemia. (Cancer Res 2006; 66(2): 622-6)
This article has been cited by other articles:
![]() |
B. J. Wouters, B. Lowenberg, and R. Delwel A decade of genome-wide gene expression profiling in acute myeloid leukemia: flashback and prospects Blood, January 8, 2009; 113(2): 291 - 298. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sauvageau, M. Miller, S. Lemieux, J. Lessard, J. Hebert, and G. Sauvageau Quantitative expression profiling guided by common retroviral insertion sites reveals novel and cell type specific cancer genes in leukemia Blood, January 15, 2008; 111(2): 790 - 799. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Lowenberg Acute Myeloid Leukemia: The Challenge of Capturing Disease Variety Hematology, January 1, 2008; 2008(1): 1 - 11. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. de Ridder, J. Kool, A. Uren, J. Bot, L. Wessels, and M. Reinders Co-occurrence analysis of insertional mutagenesis data reveals cooperating oncogenes Bioinformatics, July 1, 2007; 23(13): i133 - i141. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. S. Kustikova, H. Geiger, Z. Li, M. H. Brugman, S. M. Chambers, C. A. Shaw, K. Pike-Overzet, D. d. Ridder, F. J. T. Staal, G. v. Keudell, et al. Retroviral vector insertion sites associated with dominant hematopoietic clones mark "stemness" pathways Blood, March 1, 2007; 109(5): 1897 - 1907. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Yuan, J. E. Payton, M. S. Holt, D. C. Link, M. A. Watson, J. F. DiPersio, and T. J. Ley Commonly dysregulated genes in murine APL cells Blood, February 1, 2007; 109(3): 961 - 970. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |